Additionally, anti-FGL1 mAb treatment induced the reduction of MC38 tumors in the liver, shown by histological analysis (Figure 6D), decreased serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Figure 6E), liver weight, and hepatosomatic index (Figure 6F), indicating the effects of FGL1 blockade on tumor elimination. The gene discussed is FGL1; the disease is neoplasm.